Nektar Therapeutics (NKTR) – Analyst Ratings
-
JPMorgan Reinstates Nektar Therapeutics (NKTR) at Underweight
-
TD Cowen Upgrades Nektar Therapeutics (NKTR) to Outperform
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to NKTR Stock Lookup